Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03865667
Recruitment Status : Recruiting
First Posted : March 7, 2019
Last Update Posted : April 15, 2021
Sponsor:
Information provided by (Responsible Party):
MicroPort Orthopedics Inc.

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

Condition or disease Intervention/treatment
Joint Disease Device: PROFEMUR® Preserve Femoral Stem

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 143 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral Stem
Actual Study Start Date : January 15, 2019
Estimated Primary Completion Date : January 1, 2032
Estimated Study Completion Date : January 1, 2032

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Joint Disorders

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Primary Total Hip Arthroplasty
Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
 Device: PROFEMUR® Preserve Femoral Stem
Total Hip Total Hip Arthroscopy


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The primary endpoint is to evaluate component survivorship of the PROFEMUR® Preserve Femoral Stem and CoCr Modular Neck out to 10 years follow-up. [ Time Frame: 10 years ]
    Percentage of hips survived with no revision or replacement at 10-year.


Secondary Outcome Measures :
  1. To determine the cumulative incidence of component revision of the PROFEMUR® Preserve Femoral Stem and CoCr Modular Neck at specified intervals out to 10 years follow-up. [ Time Frame: Time Frame: 2-5 years, 5-7 years, and 10 years ]
    Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation.

  2. To characterize functional scores, as assessed by Oxford Hip and EQ-5D-3L scores. [ Time Frame: Time Frame: 2-5 years, 5-7 years, and 10 years ]
    The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'. EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems.

  3. To evaluate the presence and the zones of radiolucencies surrounding the implanted femoral components. [ Time Frame: 2-5 years, 5-7 years, and 10 years ]
    Radiolucencies are described around 7 zones and we will be reporting the number of hips with radiolucencies present at a given zone.

  4. To characterize of adverse events and adverse device effects. [ Time Frame: 2-5 years, 5-7 years, and 10 years ]
    Adverse Events will be summarized as the total number of Adverse Events (AE), Adverse Device Effect (ADE) by grade, severity, and relationship to the device and surgery. Number of patients experiencing such AEs and ADEs will be also provided.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroscopy) components including acetabular shells, acetabular liners and femoral heads.
Criteria

Newly or previously implanted subjects must meet all the following inclusion Criteria:

  • Has undergone primary Total Hip Arthroscopy for any of the following:
  • Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;lnflammatory degenerative joint disease such as rheumatoid arthritis; or
  • Correction of functional deformity;
  • Subject is implanted with the PROFEMUR® Preserve Femoral Stem(s) and cobalt-chromium Modular Neck;
  • Subject is willing and able to complete required study visits or assessments through the 10 year postoperative follow-up schedule;
  • Subject is implanted with WMT or MPO head, cup and liner.

Newly or previously implanted bilateral subjects can have both Total Hip Arthroscopy enrolled in the study provided: 1) the specified PROFEMUR® Preserve Femoral Stems and cobalt-chromium Modular Necks were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second Total Hip Arthroscopy.

Previously implanted subjects who had undergone revision of any Total Hip Arthroscopy component including the PROFEMUR® Preserve Femoral Stem(s) or, cobalt-chromium Modular Neck will also be eligible to be considered for this study.

Exclusion Criteria:

Subjects will be excluded if they meet any of the following criteria:

  • Subjects implanted with non-MicroPort or Wright Medical Technology components (femoral heads, acetabular shells, acetabular liners);
  • Subjects implanted with a PROFEMUR® Preserve stem assembled to a Titanium Modular Neck;
  • Subjects skeletally immature (less than 21 years of age) at time of primary Total Hip Arthroscopy surgery;
  • Subjects have or had an overt infection at the time of implantation;
  • Subjects have or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation;
  • Subjects have or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at time of implantation;
  • Subjects have or had inadequate neuromuscular status (e.g., prior paralysis, fusion and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable;
  • Subject has neuropathic joints;
  • Subject has hepatitis or HIV infection;
  • Subject has a neurological or musculoskeletal disease that may adversely affect gait or weight-bearing;
  • Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol;
  • Subjects unwilling or unable to sign the Informed Consent document;
  • Subjects with documented substance abuse issues;
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study;
  • Subjects who are incarcerated or have pending incarceration.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03865667


Contacts
Layout table for location contacts
Contact: Cagla Ikbal Yazici, MS +31 20 545 0162 cyazici@ortho.microport.com
Contact: Karen Martin 901-867-4712 Karen.Martin@ortho.microport.com

Locations
Layout table for location information
Spain
Dr. Manel Ribas Recruiting
Barcelona, Spain, 08028
Contact: Dr. Manel Ribas, MD         
Sponsors and Collaborators
MicroPort Orthopedics Inc.
Investigators
Layout table for investigator information
Principal Investigator: Manel Ribas, MD Hospital Universitari Dexeus
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: MicroPort Orthopedics Inc.
ClinicalTrials.gov Identifier: NCT03865667    
Other Study ID Numbers: 12-LJH-002G
First Posted: March 7, 2019    Key Record Dates
Last Update Posted: April 15, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases